Does KTWO pay a dividend and is it safe?

K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / KTWO / dividends

UTMD (62) PDEX (54) STIM (28) PROF (40) ⌘ Pro Terminal →

K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) Dividend Safety Gauge & 10-Year DRIP Compounder

$10.09 -0.30% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.07

K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $202.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KTWO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KTWO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, K2 Capital Acquisition Corporation Class A Ordinary Share (NASDAQ: KTWO) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $10.09 (-0.30% 1D, market cap $202.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, KTWO ranks #200 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KTWO compare to UTMD and PDEX in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), KTWO carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, UTMD (Utah Medical Products Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC 26.9%, cap $216.7M) and PDEX (Pro-Dex Inc.) posts a D+ grade (54/100 RQD, P/E 22.2x, ROIC 23.2%, cap $186.1M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KTWO?

▼

Per KTWO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002086524), K2 Capital Acquisition Corporation Class A Ordinary Share generated $317.0K in revenue, $0 in net income, and $0 in free cash flow against $754.7K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.07 (-0.24%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 566.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE-0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KTWO)Realized 20D OHLCV Swing Band: ±1.8%

Deterministic 5-Pillar Attribution (56/100 Composite)

🔍 WHY KTWO SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+14/20 pts (25% of score)

FRED Regime × Technicals: 89% of 52W Range • RSI-14 at 49 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$10.09+0.1% Next Q

Q2 (-2Q)

Grade C-$10.10-0.1% Next Q

Q3 (-1Q)

Grade C-$10.09+0% Next Q

Current

Grade D+$10.09-0.4% Hist 90D α

Trajectory: D (48) → D+ (56)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the KTWO Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 56/100 (D+) score, KTWO faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($10.09) or 200D SMA ($9.99) invalidates the momentum regime and cuts Target Base ($10.00) toward Bear Floor ($7.80).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KTWO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “KTWO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 56%NO 44%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KTWO)

✓Walkthrough of KTWO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KTWO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.61%📐 HORIZONTAL RANGE

2026-11-03O $10.12H $10.12L $10.09C $10.09VOL 15.8K

RES: $10.12SUP: $9.96SMA50: $10.09SMA200: $9.99

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KTWO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KTWO Butterfly Map → + Track KTWO →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KTWO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KTWO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KTWO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KTWO)

Health Care Rank #200 of 1015 ⚔️ UTMD vs KTWO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KTWO vs. UTMD, PDEX, STIM, PROF)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) ranks #200 by composite RQD confidence (56/100, grade D+) and #571 by equity capitalization ($202.2M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with KTWO at 56/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KTWO ACTIVE K2 Capital Acquisition Corporation Class A Ordinary Share	D+	56/100	—	—	—	-0.30%	$202.2M	Benchmark Subject
UTMD Utah Medical Products Inc.	C	62/100	—	57.1%	26.9%	+1.91%	$216.7M	/utmd-vs-ktwo →
PDEX Pro-Dex Inc.	D+	54/100	22.2x	29.3%	23.2%	-5.58%	$186.1M	/pdex-vs-ktwo →
STIM Neuronetics Inc.	E	28/100	—	48.5%	-35.0%	-5.46%	$171.4M	/stim-vs-ktwo →
PROF Profound Medical Corp.	D-	40/100	—	70.8%	-35.0%	+12.12%	$240.0M	/prof-vs-ktwo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002086524 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) reported GAAP revenue of $317.0K , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, KTWO closed FY2025 with $754.7K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$317.0K	$0	—	—	$754.7K	—

3. KTWO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KTWO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does KTWO compare to UTMD and PDEX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for KTWO?

Where is KTWO trading relative to its 50-day, 200-day, and 52-week technical levels?

KTWO last traded at $10.09 (-0.30% on volume of 15,826 shares), positioning the stock 0.00% above its 50-day simple moving average ($10.09) and +1.00% above its 200-day simple moving average ($9.99). Across its 52-week range of $9.84 to $10.12, KTWO sits at the 89.3% percentile with a 14-day RSI of 49.0 (NEUTRAL RANGE) and an implied next-earnings move of ±1.8% ($9.91 to $10.27).

Direct Sub-Reports: KTWO RQD Cockpit KTWO 12M Forecast KTWO Earnings & Move KTWO Dividends & DRIP KTWO Insiders & 13F KTWO Whale Options KTWO Profit Sankey KTWO News & Why

ROARABLE RATING BRIEF • RQD 56/100 (D+) ✓ SEC XBRL & RQD VERIFIED

KTWO — K2 Capital Acquisition Corporation Class A Ordinary Share: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) earns a live Roarable RQD composite score of 56/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $10.09 (-0.30% 1D, market capitalization $202.2M).

Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (10/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (14/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Per the market data, gross, operating, and net margins are each reported as 0%, and the financials section reports FY 2025 revenue as —.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) reported $317.0K in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $754.7K in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D+ • RQD 56/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 10/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $9.84 – $10.12 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector is Health Care and industry is Medical/Dental Instruments. No upstream or downstream dependencies, sector correlations, or 2nd-order bottlenecks are identified in the source data.

Key Question #1: Can KTWO sustain or expand its — operating margin and — ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $317.0K and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is KTWO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

KTWO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KTWO Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo • 6d ago

DEEP SEA MINERALS CORP. APPOINTS RAJ MATTHEW AS CHIEF FINANCIAL OFFICER

Vancouver, British Columbia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Deep Sea Minerals Corp. (CSE: SEAS) (OTCQB: DSEAF) (FSE: X450) ("Deep Sea Minerals" or the "Company"), a seabed mineral exploration and development company f

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 278d ago

K2 Capital Acquisition Corporation Announces Pricing of Upsized $120 Million Initial Public Offering

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- K2 Capital Acquisition Corporation (the "Company") today announced the pricing of its upsized initial public offering of 12,000,000 units at $10.00 per unit, with each unit con

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 5d ago

K2 Capital Acquisition Corporation Class A Ordinary Share (NASDAQ:KTWO) Stock Short Interest Report for October

<a href="https://news.google.com/rss/articles/CBMigAJBVV95cUxQSEtJbnQ1XzdQOVRtVTFoQmlQdzBqZ3BMNjNoem5TdWpMVkctQWxjdUJ2SnRkd0RnSDQwMFdSSncwZEdnbVFyRlF3T3o1TEM2N3ZoVGdsdE1VNU8xTTVvb2xlNXNJOE1tVHlzUDYzVW82MUhXeWpsTk03LUF

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 2d ago

K2 Capital Acquisition Corp (KTWO) Stock Price Prediction for 2026, 2030-2040

<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE9iaVRLdVd6QWF6RlFKZ2IwVmluMjFKRmJqamZWc1RTYVlvUFRSd0NhUk9HMjNYS1pxdS05QjZCYWd1Y2lCTzdqQUR0Q2ttRlVtSXNuQ1BFcXFGSVlqMGFsTnFXekc?oc=5" target="_blank">K2 Cap

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KTWO Bull vs. Bear Conversation Board — What's Your Call at $10.09?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KTWO 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $13.22 (+31.0%)

📌 Pinned Debate

Per the Roarable RQD rating, the Forensic Balance Sheet pillar scores 13 of 20 on an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/

Don't sleep on KTWO's setup in Health Care. Per the Roarable RQD rating, the Forensic Balance Sheet pillar scores 13 of 20 on an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (56/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@SiliconVal_Bull Agree on the RQD 56/100 quality, though with 1.0 beta I'm scaling in with half-size at $10.09 and keeping dry powder in case we test $9.38.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $8.07 (-20.0%)

Spot @ $10.09

Per the Roarable RQD rating, the Fundamental Cash Engine pillar scores 10 of 20 with ROIC at 0% and FCF yield at 0%, and the SEC financ

Fading this rally in KTWO at $10.09. Per the Roarable RQD rating, the Fundamental Cash Engine pillar scores 10 of 20 with ROIC at 0% and FCF yield at 0%, and the SEC financials report $0.0M revenue.. With a beta of 1.0 and the stock sitting at $10.09 (52-wk range $9.84–$10.12), the easy multiple expansion is already priced in.